Form: 10-Q

Quarterly report pursuant to Section 13 or 15(d)

August 7, 2024

 

Exhibit 10.1

 

AMENDMENT 1

to the

INTELLECTUAL PROPERTY CROSS-LICENSE AGREEMENT

 

This Amendment 1, by and between SpinalCyte LLC, a Texas limited liability company (“SpinalCyte”), and FibroBiologics, Inc., a Delaware corporation (“FibroBiologics”), (“Amendment 1”), amends the Intellectual Property Cross-License Agreement dated May 17, 2021, entered into by and between SpinalCyte and FibroBiologics (the “License”), and is effective as of May 17, 2021 (“Effective Date”). FibroBiologics and SpinalCyte are each referred to individually as a “Party” and collectively as the “Parties.”

 

RECITALS

 

WHEREAS, FibroBiologics and SpinalCyte are party to the Patent Assignment Agreement dated May 17, 2021 (as amended, the “Assignment”);

 

WHEREAS, the Parties inadvertently omitted certain patents and patent applications from Exhibit A to the Assignment and amended the Assignment to transfer all right, title and interest in the omitted patents and patent applications to FibroBiologics for further development (the “Revisions”); and

 

WHEREAS, the Parties desire to update the schedules in the License to reflect the Revisions.

 

NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows:

 

  1. Schedule 1 to the License is hereby amended to add the following patents and patent applications:

 

Docket Number   Country   Appl. No.   Date Filed   Patent No.   Title
AMTK.P0024AU   Australia               TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF
AMTK.P0024CA   Canada               TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF
AMTK.P0024EP   European Patent Office               TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF
AMTK.P0024JP   Japan               TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF
AMTK.P0024US   United States of America   17/309177   5/3/2021       TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF

 

     
 

 

AMTK.P0024US.Pl   United States of America   62/755542   11/4/2018       TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF
AMTK.P0024WO   Patent Cooperation Treaty   PCT/US2019/059678   11/4/2019       TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF
AMTK.P0026AU   Australia               REGENERATIVE ABSCOPAL EFFECTS
AMTK.P0026CA   Canada               REGENERATIVE ABSCOPAL EFFECTS
AMTK.P0026EP  

European

Patent Office

  19881814.8           REGENERATIVE ABSCOPAL EFFECTS
AMTK.P0026JP   Japan               REGENERATIVE ABSCOPAL EFFECTS
AMTK.P0026US  

United

States of America

  17/309207   5/6/2021       REGENERATIVE ABSCOPAL EFFECTS
AMTK.P0026US.Pl   United States of America   62/757764   11/9/2018       REGENERATIVE ABSCOPAL EFFECTS
AMTK.P0026WO  

Patent

Cooperation Treaty

  PCT/US2019/060397   11/8/2019       REGENERATIVE ABSCOPAL EFFECTS

 

     
 

 

  2. Schedule 2 to the License is hereby amended to remove the following patents and patent applications:

 

Docket Number   Country   Appl. No.   Date Filed   Patent No.   Title
AMTK.P0024AU   Australia               TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF
AMTK.P0024CA   Canada               TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF
AMTK.P0024EP   European Patent Office               TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF
AMTK.P0024JP   Japan               TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF
AMTK.P0024US   United States of America   17/309177   5/3/2021       TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF
AMTK.P0024US.Pl   United States of America   62/755542   11/4/2018       TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF
AMTK.P0024WO   Patent Cooperation Treaty   PCT/US2019/059678   11/4/2019       TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF
AMTK.P0026AU   Australia               REGENERATIVE ABSCOPAL EFFECTS
AMTK.P0026CA   Canada               REGENERATIVE ABSCOPAL EFFECTS
AMTK.P0026EP  

European

Patent Office

  19881814.8           REGENERATIVE ABSCOPAL EFFECTS
AMTK.P0026JP   Japan               REGENERATIVE ABSCOPAL EFFECTS
AMTK.P0026US  

United

States of America

  17/309207   5/6/2021       REGENERATIVE ABSCOPAL EFFECTS
AMTK.P0026US.Pl   United States of America   62/757764   11/9/2018       REGENERATIVE ABSCOPAL EFFECTS
AMTK.P0026WO  

Patent

Cooperation Treaty

  PCT/US2019/060397   11/8/2019       REGENERATIVE ABSCOPAL EFFECTS

 

All other terms and conditions of the License shall remain in full force and effect and no other changes are made as a result of this Amendment 1.

 

[Signature Page Follows]

 

     
 

 

IN WITNESS WHEREOF, the Parties hereto have caused this Amendment 1 to be executed by their duly authorized officers to be effective as of the Effective Date.

 

FibroBiologics, Inc.

 

/s/ Pete O’Heeron  
Name: Pete O’Heeron  
Title: Chief Executive Officer  
Date: 8/5/2024  

 

Spinalcyte, LLC

 

/s/ Pete O’Heeron  
Name: Pete O’Heeron  
Title: Manager  
Date: 8/5/2024